SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study
Clinical trial NCT07417241 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07417241
- Sponsor
- Peking University Cancer Hospital & Institute
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-03-31
- Primary completion
- 2029-01-31
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.